ES2069836T3 - Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1). - Google Patents

Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).

Info

Publication number
ES2069836T3
ES2069836T3 ES91311583T ES91311583T ES2069836T3 ES 2069836 T3 ES2069836 T3 ES 2069836T3 ES 91311583 T ES91311583 T ES 91311583T ES 91311583 T ES91311583 T ES 91311583T ES 2069836 T3 ES2069836 T3 ES 2069836T3
Authority
ES
Spain
Prior art keywords
indol
dimethylamine
ethyl
methyl
methanosulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91311583T
Other languages
English (en)
Inventor
Joanne Craig
Derek Leslie Crookes
Stephen John Skittrall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2069836T3 publication Critical patent/ES2069836T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

SE REVELA UNA SAL DE SULFATO 3-(2-DIMETILAMINO)ETIL)-N-METIL-1H-INDOL-5 -METANOSULFONAMIDA (2:1) Y SOLVATADOS FARMACEUTICAMENTE ACEPTABLE DE LO MISMO. EL COMPUESTO ES DE UTILIDAD EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS, PARTICULARMENTE PARA FORMULACIONES INTRANASALES, PARA UTILIZAR EN EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON DOLOR DE CABEZA, EN PARTICULAR MIGRAÑA.
ES91311583T 1990-12-12 1991-12-12 Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1). Expired - Lifetime ES2069836T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (1)

Publication Number Publication Date
ES2069836T3 true ES2069836T3 (es) 1995-05-16

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91311583T Expired - Lifetime ES2069836T3 (es) 1990-12-12 1991-12-12 Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).

Country Status (36)

Country Link
US (2) US5554639A (es)
EP (1) EP0490689B1 (es)
JP (1) JP2994037B2 (es)
KR (1) KR100211479B1 (es)
CN (2) CN1030890C (es)
AP (1) AP230A (es)
AT (1) ATE119881T1 (es)
AU (1) AU650706B2 (es)
BE (1) BE1005085A3 (es)
CA (1) CA2098302C (es)
CH (1) CH684192A5 (es)
CY (1) CY2005A (es)
CZ (1) CZ281931B6 (es)
DE (1) DE69108200T2 (es)
DK (1) DK0490689T3 (es)
EG (1) EG20219A (es)
ES (1) ES2069836T3 (es)
FR (1) FR2670487B1 (es)
GB (2) GB9026998D0 (es)
GR (1) GR3015430T3 (es)
HK (1) HK82697A (es)
HU (1) HU211937A9 (es)
IE (1) IE62894B1 (es)
IL (1) IL100330A (es)
IS (1) IS1706B (es)
IT (1) IT1252868B (es)
MX (1) MX9102501A (es)
MY (1) MY109265A (es)
NL (1) NL9102071A (es)
NZ (1) NZ240942A (es)
PT (1) PT99757B (es)
RU (1) RU2108328C1 (es)
TW (2) TW205035B (es)
WO (1) WO1992010477A1 (es)
YU (1) YU48926B (es)
ZA (1) ZA919750B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116411T3 (es) * 1992-06-05 1998-07-16 Merck Sharp & Dohme La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en) 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050269402A1 (en) * 2004-06-03 2005-12-08 Tyfone, Inc. System and method for securing financial transactions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
MX2010013019A (es) 2008-05-27 2011-03-21 Biota Scient Management Pty Ltd Sales antivirales.
CA2765866C (en) * 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
EP2480197B1 (en) 2009-09-25 2015-11-11 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
ES2842523T3 (es) 2015-05-15 2021-07-14 Univ Michigan Regents Métodos y composiciones para el tratamiento de la artritis
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
CN111315383B (zh) 2017-11-07 2023-09-29 密执安大学评议会 共享表位-钙网蛋白相互作用的小分子抑制剂和使用方法
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
KR20220146535A (ko) * 2020-02-27 2022-11-01 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 리메게판트의 경구 급속-분산성 투여 형태

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
IS3790A7 (is) 1992-06-13
IL100330A (en) 1996-06-18
GB9026998D0 (en) 1991-01-30
CA2098302A1 (en) 1992-06-13
DE69108200D1 (de) 1995-04-20
RU2108328C1 (ru) 1998-04-10
MX9102501A (es) 1992-09-01
PT99757B (pt) 1999-05-31
CN1050831C (zh) 2000-03-29
AU9072091A (en) 1992-07-08
HK82697A (en) 1997-06-27
DK0490689T3 (da) 1995-05-22
IT1252868B (it) 1995-06-28
GB2251614A (en) 1992-07-15
US5705520A (en) 1998-01-06
MY109265A (en) 1996-12-31
BE1005085A3 (fr) 1993-04-13
CH684192A5 (fr) 1994-07-29
NZ240942A (en) 1994-03-25
WO1992010477A1 (en) 1992-06-25
TW205035B (es) 1993-05-01
YU48926B (sh) 2002-12-10
ITRM910922A1 (it) 1993-06-11
IS1706B (is) 1998-12-10
KR100211479B1 (ko) 1999-08-02
CY2005A (en) 1997-12-05
HU211937A9 (en) 1996-01-29
ATE119881T1 (de) 1995-04-15
DE69108200T2 (de) 1995-07-20
CZ281931B6 (cs) 1997-04-16
CN1063099A (zh) 1992-07-29
CA2098302C (en) 2001-10-16
FR2670487B1 (fr) 1993-08-20
AU650706B2 (en) 1994-06-30
ITRM910922A0 (it) 1991-12-11
EP0490689A1 (en) 1992-06-17
AP230A (en) 1993-01-27
PT99757A (pt) 1992-12-31
CN1030890C (zh) 1996-02-07
IL100330A0 (en) 1992-09-06
IE62894B1 (en) 1995-03-08
FR2670487A1 (fr) 1992-06-19
NL9102071A (nl) 1992-07-01
EG20219A (en) 1997-11-30
CN1128259A (zh) 1996-08-07
ZA919750B (en) 1992-10-28
TW300886B (es) 1997-03-21
EP0490689B1 (en) 1995-03-15
US5554639A (en) 1996-09-10
GB9126297D0 (en) 1992-02-12
JP2994037B2 (ja) 1999-12-27
YU191491A (sh) 1994-04-05
IE914317A1 (en) 1992-06-17
JPH06503560A (ja) 1994-04-21
CZ114093A3 (en) 1994-02-16
GR3015430T3 (en) 1995-06-30
GB2251614B (en) 1994-12-14
AP9100339A0 (en) 1992-01-31

Similar Documents

Publication Publication Date Title
MY109265A (en) A salt of 3-[2-(diamethylamino) ethyl]-n-methyl-1h-indole-5-methanesulphonamide
RU93053493A (ru) Сульфатная соль (2:1)-3-[2-(диметиламино)этил]-n-метил-1н-индол-5-метансульфонамида и ее фармацевтически приемлемые сольваты, способ их получения, фармацевтические композиции на их основе, их применение в терапии, способ лечения головной боли
ES2145922T3 (es) Compuestos espiro-azabiciclicos utiles en terapia.
DE3572481D1 (en) 3-substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
ES2117015T3 (es) Composiciones que contienen sumatriptan.
NO963053L (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
NO174100C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive piperidinylforbindelser
PH17786A (en) New methyl substituted 4-methoxy-pyridine-n-oxides to be used as intermediate in the preparation of the new intermediate
RU94035686A (ru) 4-ариламино-бензопиран и родственные соединения, фармацевтическая композиция, способ лечения
CA2268840A1 (en) Benzimidazole-2-carbamates for the treatment of viral infections and cancer
HUT41402A (en) Fungicide compositions containing azolyl-methyl-oxirane derivatives and process for preparing the active ingredients
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
NZ332608A (en) alkyl 17-alpha-dichloroacetoxy-11- beta-hydroxy-androsta-1,4-diene-3-one-17-beta-carboxylates and medicaments
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
NO302471B1 (no) Tiazolidinforbindelser og farmasöytisk preparat
NO971625L (no) Nye peptider med immunomodulatoriske effekter
ATE228364T1 (de) Indolalkaloide als antientzündliche wirkstoffe
ZA922482B (en) Pharmacologically enhanced formulations
DE3767114D1 (de) Stabilisierte arzneimittel.
YU31592A (sh) 6-HETEROCIKLIČNI-4-AMINO-1,2,2a,3,4,5- HEKSAHIDROBENZ (cd) INDOLI
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
AU2845489A (en) Process for preparing hydroxyakylating agents, the agents so obtained, and their use
SE8704240L (sv) Analgetiska preparat
AU541018B2 (en) Sulphones (sulphoxide)phenoxy alkanol amines
DE3465594D1 (en) Tropone derivatives, processes for preparation thereof and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490689

Country of ref document: ES